Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Stem cells after myocardial infarction].

Volker Schächinger1, Stefanie Dimmeler, Andreas M Zeiher

  • 1Medizinische Klinik III/Kardiologie, J.W.-Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt. schaechinger@em.uni-frankfurt.de

Herz
|June 2, 2006
PubMed
Summary

Transplanting progenitor cells after myocardial infarction improves heart function and vascularization. Larger trials are needed to confirm effects on mortality and morbidity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Independent and Dose-Dependent Contributions of Clonal Hematopoiesis and Mosaic Loss of Y to Incident Heart Failure.

European journal of heart failure·2026
Same author

Geriatric nutritional risk index associated to long-term prognosis and length of hospitalization in the contemporary transcatheter aortic valve replacement era.

Journal of geriatric cardiology : JGC·2026
Same author

Endothelial ZBTB16: a molecular shield against cardiac aging.

European heart journal·2026
Same author

Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells.

Cardiovascular research·2025
Same author

Relevance of Clonal Hematopoiesis in Immune Cells for Degenerative Aortic Valve Stenosis.

Journal of the American Heart Association·2025
Same author

Clonal hematopoiesis activates procalcific pathways in macrophages and promotes aortic valve stenosis.

The Journal of clinical investigation·2025

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Stem Cell Therapy

Background:

  • Myocardial infarction leads to left ventricular remodeling and heart failure.
  • Regenerating cardiomyocytes and improving neovascularization are key therapeutic goals.
  • Adult stem and progenitor cells show promise in preclinical models.

Purpose of the Study:

  • To evaluate the therapeutic potential of progenitor cell transplantation after myocardial infarction.
  • To assess the safety and efficacy of intracoronary progenitor cell infusion.
  • To investigate the impact on left ventricular function, geometry, and vascularization.

Main Methods:

  • Intracoronary transplantation of adult progenitor cells (e.g., CPCs).
  • Assessment of left ventricular function, geometry, and vascularization post-transplantation.
  • Clinical trials including randomized, placebo-controlled studies (e.g., REPAIR-AMI).

Main Results:

  • Progenitor cell transplantation is feasible and safe in acute myocardial infarction patients.
  • Significant improvements in left ventricular function, geometry, and vascularization observed.
  • The REPAIR-AMI trial showed significant LV function improvement in treated patients.

Conclusions:

  • Intracoronary progenitor cell infusion is a promising strategy post-myocardial infarction.
  • Further large-scale, randomized trials are warranted to confirm effects on mortality and morbidity.
  • Validated progenitor cell processing is crucial for therapeutic efficacy.

Related Experiment Videos